HNF Awards the inaugural HNF Clinical Translation Fellowship

by | Aug 16, 2024 | 2 comments

HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla Cornett, PhD

We are thrilled to announce the establishment of the HNF Clinical Translation Fellowship, awarded to Kayla Cornett, PhD, a distinguished postdoctoral research fellow at the University of Sydney and the Children’s Hospital at Westmead. Dr. Cornett is recognized for her expertise in clinical outcome measurement for pediatric neuromuscular diseases, particularly Charcot-Marie-Tooth (CMT).

About Dr. Kayla Cornett

Dr. Cornett’s work is at the forefront of pediatric neuromuscular research. As an early-career researcher, she has already authored over 45 publications, including a seminal report in the Annals of Neurology on the natural history of CMT during childhood. Her collaborative efforts with leading researchers worldwide have significantly advanced the reliable and sensitive assessment of function in children with neuromuscular diseases.

Fellowship Overview

As the landscape of drug development for CMT rapidly evolves, with therapies like small molecules, RNA-targeted therapies, and gene replacement advancing toward clinical application, the need for tailored clinical trial outcome measures has never been more critical. This fellowship aims to address this need by developing new measurement tools, including remote tools for tracking disease progress, training clinicians, assessing patient natural history through global expansion of the GRIN patient registry, and disseminating valuable information to the global CMT community.

Impact on the CMT Community

This fellowship will play a pivotal role in advancing clinical research and care for CMT patients. The work undertaken by Dr. Cornett will not only improve the precision of clinical trials for both adults and children, but also provide more accurate and meaningful assessments of patient outcomes. The expansion of GRIN globally will enable more comprehensive data collection, ultimately leading to better-informed treatments and therapies for those affected by CMT.

We are excited to support Dr. Cornett’s groundbreaking work and look forward to the significant contributions she will make to the field of CMT research.

Stay tuned for updates on her progress and the impact of this fellowship on the global CMT community.

 

Learn more on this topic

Related Blog Posts

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Join the conversation

Leave a Comment

2 Comments

  1. Laure Ebel

    Where can I get information specifically regarding HNPP ?

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news